Literature DB >> 2118819

6-Hydroxydopamine lesions of the ventral tegmentum abolish D-amphetamine and morphine analgesia in the formalin test but not in the tail flick test.

M J Morgan1, K B Franklin.   

Abstract

The effect of bilateral 6-hydroxdopamine (with desipramine) lesions of the ventral tegmental area-substantia nigra region on analgesia produced by morphine and D-amphetamine was examined with the formalin and tail flick tests in rats. These lesions depleted dopamine, but not noradrenaline, in the ventral and anterior striatum. Morphine and D-amphetamine produced analgesia in the formalin test in sham lesioned rats but not in lesioned rats. In contrast, morphine produced the same degree of analgesia in the tail flick test in sham lesioned and lesioned rats while D-amphetamine did not produce analgesia in this test. These data suggest that morphine and D-amphetamine analgesia in the formalin test involves dopamine, whereas morphine analgesia in the tail flick test does not.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118819     DOI: 10.1016/0006-8993(90)90072-j

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

Review 1.  Corticolimbic circuitry in the modulation of chronic pain and substance abuse.

Authors:  Anna M W Taylor
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-05-10       Impact factor: 5.067

2.  Neuroinflammation-a co-occurring phenomenon linking chronic pain and opioid dependence.

Authors:  Catherine M Cahill; Anna Mw Taylor
Journal:  Curr Opin Behav Sci       Date:  2017-01-06

Review 3.  Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions.

Authors:  Amanda L-C Chen; Thomas J H Chen; Roger L Waite; Jeffrey Reinking; Howard L Tung; Patrick Rhoades; B William Downs; Eric Braverman; Dasha Braverman; Mallory Kerner; Seth H Blum; Nicholas DiNubile; David Smith; Marlene Oscar-Berman; Thomas J Prihoda; John B Floyd; David O'Brien; H H Liu; Kenneth Blum
Journal:  Med Hypotheses       Date:  2008-10-31       Impact factor: 1.538

4.  Affective analgesia following muscarinic activation of the ventral tegmental area in rats.

Authors:  Robert G Kender; Steven E Harte; Elizabeth M Munn; George S Borszcz
Journal:  J Pain       Date:  2008-04-03       Impact factor: 5.820

5.  Periaqueductal gray afferents synapse onto dopamine and GABA neurons in the rat ventral tegmental area.

Authors:  Natalia Omelchenko; Susan R Sesack
Journal:  J Neurosci Res       Date:  2010-04       Impact factor: 4.164

6.  Stimulation of the ventral tegmental area increased nociceptive thresholds and decreased spinal dorsal horn neuronal activity in rat.

Authors:  Ai-Ling Li; Jiny E Sibi; Xiaofei Yang; Jung-Chih Chiao; Yuan Bo Peng
Journal:  Exp Brain Res       Date:  2016-01-28       Impact factor: 1.972

7.  D2 Receptors in the Periaqueductal Gray/Dorsal Raphe Modulate Peripheral Inflammatory Hyperalgesia via the Rostral Ventral Medulla.

Authors:  Luiz F Ferrari; JunZhu Pei; Michael Zickella; Charles Rey; Jacqueline Zickella; Anna Ramirez; Norman E Taylor
Journal:  Neuroscience       Date:  2021-04-04       Impact factor: 3.590

8.  Doubling Your Payoff: Winning Pain Relief Engages Endogenous Pain Inhibition

Authors:  Susanne Becker; Wiebke Gandhi; Saskia Kwan; Alysha-Karima Ahmed; Petra Schweinhardt
Journal:  eNeuro       Date:  2015-09-17

9.  Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum.

Authors:  Ilkka K Martikainen; Emily B Nuechterlein; Marta Peciña; Tiffany M Love; Chelsea M Cummiford; Carmen R Green; Christian S Stohler; Jon-Kar Zubieta
Journal:  J Neurosci       Date:  2015-07-08       Impact factor: 6.167

10.  Lesion of the dopaminergic nigrostriatal pathway induces trigeminal dynamic mechanical allodynia.

Authors:  Wisam Dieb; Omar Ouachikh; Franck Durif; Aziz Hafidi
Journal:  Brain Behav       Date:  2014-02-20       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.